Utilizing UL97 Resistant Codon Specificities to Guide Pharmacotherapy Treatment Decisions in Resistant Cytomegalovirus Infections
Received Date: Feb 28, 2018 / Accepted Date: Mar 22, 2018 / Published Date: Mar 26, 2018
Abstract
The development of cytomegalovirus (CMV) drug resistance has become an emerging clinical challenge. In kidney transplant recipients (KTR), CMV infection is a risk factor for acute rejection, has a detrimental effect on patient survival, and predisposes patients to secondary opportunistic infections. We report here the case of a kidney transplant patient on valganciclovir prophylaxis who developed recurrent CMV infections, complicated by UL97 ganciclovir (GCV) resistance. Our patient underwent unsuccessful treatment courses with high dose GCV, foscarnet and cidofovir. Compassionate use maribavir was initiated and resulted in full recovery. Through this case report and literature review, we highlight potential strategies for the successful management of CMV resistance.
Keywords: cytomegalovirus, transplantation, transplant recipient, bone marrow suppression, immunosuppression.
Citation: Maldonado AQ, Leeser DB, Asempa TE (2018) Utilizing UL97 Resistant Codon Specificities to Guide Pharmacotherapy Treatment Decisions in Resistant Cytomegalovirus Infections. J Clin Exp Transplant 3: 119. Doi: 10.4172/2475-7640.1000119
Copyright: © 2018 Maldonado AQ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Open Access Journals
Article Tools
Article Usage
- Total views: 3759
- [From(publication date): 0-2018 - Apr 27, 2024]
- Breakdown by view type
- HTML page views: 3156
- PDF downloads: 603
